Journal Section:
Erratum

In the article “Clinical Impact of Early Tumour Shrinkage in Metastatic or Unresectable Oesophageal Cancer Treated with Pembrolizumab plus Chemotherapy” [Oncology 2024;102(6):484–493. DOI: 10.1159/000535186] by Sugase et al., the values of the median follow-up period were used in place of the median progression-free survival period. The following corrections should be observed.

The median period was incorrectly described as:

The median progression-free survival (PFS) and overall survival for ETS ≥20% and <20% were 12.7 and 5.5 months and 14.4 and 8.2 months and 12.7 and 4.9 months and 14.4 and 8.0 months for DpR ≥30% and <30%, respectively.

The correct description of the period is:

The median progression-free survival (PFS) and overall survival for ETS ≥20% and <20% were not reached (NR) and 5.5 months and NR and 9.5 months and NR and 4.9 months and NR and 8.3 months for DpR ≥30% and <30%, respectively.

Early Tumour Shrinkage

The median period was incorrectly described as:

Patients with ETS <20% and ≥20% had median PFS of 12.7 months and 5.5 months, respectively (HR 0.11, 95% CI: 0.05–0.27, p < 0.001). All patients with ETS <20% had disease progression within 1 year of the date of diagnosis of metastatic or unresectable disease. Patients with ETS ≥20% and <20% had median OS durations of 14.4 months and 8.2 months, respectively (HR 0.10, 95% CI: 0.04–0.29, p < 0.001).

The correct description of the period is:

The median PFS of patients with ETS <20% and ≥20% was not reached (NR) and 5.5 months, respectively (HR 0.11, 95% CI: 0.05–0.27, p < 0.001). All patients with ETS <20% had disease progression within 1 year of the date of diagnosis of metastatic or unresectable disease. The median OS of patients with ETS ≥20% and <20 was NR and 9.5 months, respectively (HR 0.10, 95% CI: 0.04–0.29, p < 0.001).

Depth of Response

The median period was incorrectly described as:

Patients with a DpR of ≥30% and <30% had median PFS of 12.7 months and 4.9 months, respectively (HR 0.10, 95% CI: 0.04–0.23, p < 0.001). All patients with DpR <30% had disease progression within 1 year of the date of diagnosis of metastatic or unresectable disease. Patients with DpR ≥30% and <30% had median OS of 14.4 months and 8.0 months, respectively (HR 0.12, 95% CI: 0.05–0.32, p < 0.001).

The correct description of the period is:

The median PFS of patients with a DpR of ≥30% and <30% was NR and 4.9 months, respectively (HR 0.10, 95% CI: 0.04–0.23, p < 0.001). All patients with DpR <30% had disease progression within 1 year of the date of diagnosis of metastatic or unresectable disease. The median OS of patients with DpR ≥30% and <30% was NR and 8.2 months, respectively (HR 0.12, 95% CI: 0.05–0.32, p < 0.001).

The median period was incorrectly described as:

In the present study, patients with ETS ≥20% showed a sufficient long-term response (median PFS 12.7 months) compared to the previous study with chemotherapy alone (median PFS 7.5 months).

The correct description of the period is:

In the present study, patients with ETS ≥20% showed a sufficient long-term response compared to the previous study with chemotherapy alone (median PFS 7.5 months).

© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024